Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
iShares 10 20 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.78 (market cap $5.07B), while iShares 10 20 Year Treasury Bond ETF trades at $96.76. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

ACADTLH
Market Cap
$5.07B
Sector
HealthFixed Income
52-Week High
$29.41$105.36
52-Week Low
$20.06$96.39
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

iShares 10 20 Year Treasury Bond ETF

TLH trades at $96.86, up 0.49% today, but technical indicators signal a bearish trend with moving averages and ADX pointing downward. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent corporate actions include consistent dividend payments, with the latest being $0.38 per share scheduled for August 2026. Market sentiment is influenced by broader economic factors like rising Treasury yields and oil price volatility, as highlighted in recent financial news.

The outlook for TLH is cautious due to weak technical momentum and absent key financial metrics, though dividend stability offers some support. Risks include macroeconomic pressures from potential Fed rate hikes and inflation. Investors should seek updated earnings reports for fundamental reassessment, as current data gaps hinder a full evaluation of growth prospects or valuation attractiveness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About iShares 10 20 Year Treasury Bond ETF

TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.

Read more on TLH